[1]
|
N. van Belzen, W. N. Dinjens, M. P. Diesveld, N. A. Groen, A. C. van der Made, Y. Nozawa, et al., “A Novel Gene Which Is Up-Regulated during Colon Epithelial Cell Differentiation and Down-Regulated in Colorectal Neoplasms,” Laboratory Investigation, Vol. 77, No. 1, 1997, pp. 85-92.
|
[2]
|
K. Kokame, H. Kato and T. Miyata, “Homocysteine-Respondent Genes in Vascular Endothelial Cells Identified by Differential Display Analysis. GRP78/BiP and Novel Genes,” The Journal of Biological Chemistry, Vol. 271, No. 47, 1996, pp. 29659-29665.
doi:10.1074/jbc.271.47.29659
|
[3]
|
D. Zhou, K. Salnikow and M. Costa, “Cap43, a Novel Gene Specifically Induced by Ni2+ Compounds,” Cancer Research, Vol. 58, No. 10, 1998, pp. 2182-2189.
|
[4]
|
S. K. Kurdistani, P. Arizti, C. L. Reimer, M. M. Sugrue, S. A. Aaronson and S. W. Lee, “Inhibition of Tumor Cell Growth by RTP/Rit42 and Its Responsiveness to p53 and DNA Damage,” Cancer Research, Vol. 58, No. 19, 1998, pp. 4439-4444.
|
[5]
|
H. Park, M. A. Adams, P. Lachat, F. Bosman, S. C. Pang and C. H. Graham, “Hypoxia Induces the Expression of a 43-kDa Protein (PROXY-1) in Normal and Malignant Cells,” Biochemical and Biophysical Research Communications, Vol. 276, No. 1, 2000, pp. 321-328.
doi:10.1006/bb rc.2000.3475
|
[6]
|
D. Piquemal, D. Joulia, P. Balaguer, A. Basset, J. Marti and T. Commes, “Differential Expression of the RTP/ Drg1/Ndr1 Gene Product in Proliferating and Growth Arrested Cells,” Biochimica et Biophysica Acta, Vol. 1450, No. 3, 1999, pp. 364-373.
doi:10.1016/S0167-4889(99)00056-7
|
[7]
|
Y. Taketomi, T. Sugiki, T. Saito, S. Ishii, M. Hisada, T. Suzuki-Nishimura, et al., “Identification of NDRG1 as an Early Inducible Gene during in Vitro Maturation of Cultured Mast Cells,” Biochemical and Biophysical Research Communications, Vol. 306, No. 2, 2003, pp. 339-346.
doi:10.1016/S0006-291X(03)00942-2
|
[8]
|
K. Salnikow, M. V. Blagosklonny, H. Ryan, R. Johnson and M. Costa, “Carcinogenic Nickel Induces Genes Involved with Hypoxic Stress,” Cancer Research, Vol. 60, No. 1, 2000, pp. 38-41.
|
[9]
|
S. Bandyopadhyay, S. K. Pai, S. C. Gross, S. Hirota, S. Hosobe, K. Miura, et al., “The Drg-1 Gene Suppresses Tumor Metastasis in Prostate Cancer,” Cancer Research, Vol. 63, No. 8, 2003, pp. 1731-1736.
|
[10]
|
S. Bandyopadhyay, S. K. Pai, S. Hirota, S. Hosobe, Y. Takano, K. Saito, et al., “Role of the Putative Tumor Metastasis Suppressor Gene Drg-1 in Breast Cancer Progression,” Oncogene, Vol. 23, No. 33, 2004 , pp. 5675-5681. doi:10.1038/sj.onc.1207734
|
[11]
|
L. C. Tu, X. Yan, L. Hood and B. Lin, “Proteomics Analysis of the Interactome of N-MYC Downstream Regulated Gene 1 and Its Interactions with the Androgen Response Program in Prostate Cancer Cells,” Molecular & Cellular Proteomics, Vol. 6, No. 4, 2007, pp. 575-588. doi:10.1074/mcp.M600249-MCP200
|
[12]
|
R. J. Guan, H. L. Ford, Y. Fu, Y. Li, L. M. Shaw and A. B. Pardee, “Drg-1 as a Differentiation-Related, Putative Metastatic Suppressor Gene in Human Colon Cancer,” Cancer Research, Vol. 60, No. 3, 2000, pp. 749-755.
|
[13]
|
S. Bandyopadhyay, S. K. Pai, S. Hirota, S. Hosobe, T. Tsukada, K. Miura, et al., “PTEN Up-Regulates the Tumor Metastasis Suppressor Gene Drg-1 in Prostate and Breast Cancer,” Cancer Research, Vol. 64, No. 21, 2004, pp. 7655-7660. doi:10.1158/0008-5472.CAN-04-1623
|
[14]
|
M. S. Chua, H. Sun, S. T. Cheung, V. Mason, J. Higgins, D. T. Ross, et al., “Overexpression of NDRG1 is an Indicator of Poor Prognosis in Hepatocellular Carcinoma,” Modern Pathology, Vol. 20, No. 1, 2007, pp. 76-83.
doi:10.1038/modpathol.3800711
|
[15]
|
K. Masuda, M. Ono, M. Okamoto, W. Morikawa, M. Otsubo, T. Migita, et al., “Downregulation of Cap43 Gene by von Hippel-Lindau Tumor Suppressor Protein in Human Renal Cancer Cells,” International Journal of Cancer, Vol. 105, No. 6, 2003, pp. 803-810.
|
[16]
|
A. Nishie, K. Masuda, M. Otsubo, T. Migita, M. Tsuneyoshi, K. Kohno, et al., “High Expression of the Cap43 Gene in Infiltrating Macrophages of Human Renal Cell Carcinomas,” Clinical Cancer Research: An Official Journal of the American Association for Cancer Research, Vol. 7, No. 7, 2001, pp. 2145-2151.
|
[17]
|
J. Chen, S. Li, Z. Yang, G. Lu and H. Hu, “Correlation between NDRG1 and PTEN Expression in Endometrial Carcinoma,” Cancer Science, Vol. 99, No. 4, 2008, pp. 706-710. doi:10.1111/j.1349-7006.2008.00749.x
|
[18]
|
P. Lachat, P. Shaw, S. Gebhard, N. van Belzen, P. Chaubert and F. T. Bosman, “Expression of NDRG1, a Differentiation-Related Gene, in Human Tissues,” Histochemistry and Cell Biology, Vol. 118, No. 5, 2002, pp. 399-408. doi:10.1007/s00418-002-0460-9
|
[19]
|
N. Barboule, V. Baldin, S. Jozan, S. Vidal and A. Valette, “Increased Level of p21 in Human Ovarian Tumors Is Associated with Increased Expression of CDK2, Cyclin A and PCNA,” International Journal of Cancer, Vol. 76, No. 6, 1998, pp. 891-896.
|
[20]
|
F. Terauchi, A. Okamoto, T. Nagashima, Y. Kobayashi, T. Moritake, Y. Yamamoto, et al., “Clinical Significance of p21(WAF1/CIP1) and p53 Expression in Serous Cystadenocarcinoma of the Ovary,” Oncology Reports, Vol. 14, No. 2, 2005, pp. 363-368.
|
[21]
|
L. G. Buchynska, I. P. Nesina, N. P. Yurchenko, O. O. Bilyk, V. N. Grinkevych and V. S. Svintitsky, “Expression of p53, p21WAF1/CIP1, p16INK4A and Ki-67 Proteins in Serous Ovarian Tumors,” Experimental Oncology, Vol. 29, No. 1, 2007, pp. 49-53.
|
[22]
|
A. Marchetti, F. Buttitta, S. Pellegrini, G. Bertacca, A. Lori and G. Bevilacqua, “Absence of Somatic Mutations in the Coding Region of the waf1/cip1 Gene in Human Breast, Lung and Ovarian Carcinomas—A Polymorphism at Codon-31,” International Journal of Oncology, Vol. 6, No. 1, 1995, pp. 187-189.
|
[23]
|
M. Esteller, “Epigenetics in Cancer,” The New England Journal of Medicine, Vol. 358, No. 11, 2008, pp. 1148-1159. doi:10.1056/NEJMra072067
|
[24]
|
I. Ibanez de Caceres, C. Battagli, M. Esteller, J. G. Herman, E. Dulaimi, M. I. Edelson, et al., “Tumor Cell-Specific BRCA1 and RASSF1A Hypermethylation in Serum, Plasma, and Peritoneal Fluid from Ovarian Cancer Patients,” Cancer Research, Vol. 64, No. 18, 2004, pp. 6476-6481. doi:10.1158/0008-5472.CAN-04-1529
|
[25]
|
D. H. Shen, K. Y. Chan, U. S. Khoo, H. Y. Ngan, W. C. Xue, P. M. Chiu, et al., “Epigenetic and Genetic Alterations of p33ING1b in Ovarian Cancer,” Carcinogenesis, Vol. 26, No. 4, 2005, pp. 855-863.
doi:10.1093/carcin/bgi011
|
[26]
|
W. Feng, R. T. Marquez, Z. Lu, J. Liu, K. H. Lu, J. P. Issa, et al., “Imprinted Tumor Suppressor Genes ARHI and PEG3 Are the Most Frequently Down-Regulated in Human Ovarian Cancers by Loss of Heterozygosity and Promoter Methylation,” Cancer, Vol. 112, No. 7, 2008, pp. 1489-1502. doi:10.1002/cncr.23323
|
[27]
|
K. Selvendiran, L. Tong, S. Vishwanath, A. Bratasz, N. J. Trigg, V. K. Kutala, et al., “EF24 Induces G2/M Arrest and Apoptosis in Cisplatin-Resistant Human Ovarian Cancer Cells by Increasing PTEN Expression,” The Journal of Biological Chemistry, Vol. 282, No. 39, 2007, pp. 28609-28618. doi:10.1074/jbc.M703796200
|
[28]
|
H. Wu, S. Wang, D. Weng, H. Xing, X. Song, T. Zhu, et al., “Reversal of the Malignant Phenotype of Ovarian Cancer A2780 Cells through Transfection with WildType PTEN Gene,” Cancer Letters, Vol. 271, No. 2, 2008, pp. 205-214. doi:10.1016/j.canlet.2008.06.018
|
[29]
|
Y. Takei, Y. Saga, H. Mizukami, T. Takayama, M. Ohwada, K. Ozawa, et al., “Over Expression of PTEN in Ovarian Cancer Cells Suppresses I.P. Dissemination and Extends Survival in Mice,” Molecular Cancer Therapeutics, Vol. 7, No. 3, 2008, pp. 704-711.
doi:10.1158/1535-7163.MCT-06-0724
|
[30]
|
Z. Ju, A. R. Choudhury and K. L. Rudolph, “A Dual Role of p21 in Stem Cell Aging,” Annals of the New York Academy of Sciences, Vol. 1100, 2007, pp. 333-344.
doi:10.1196/annals.1395.036
|
[31]
|
A. Viale, F. De Franco, A. Orleth, V. Cambiaghi, V. Giuliani, D. Bossi, et al., “Cell-Cycle Restriction Limits DNA Damage and Maintains Self-Renewal of Leukaemia Stem Cells,” Nature, Vol. 457, No. 7225, 2009, pp. 51-56. doi:10.1038/nature07618
|